Nexalin Technology, Inc. (NXLIW)

US — Healthcare Sector
Peers: NXGLW  PETVW  NLSPW  HSCSW  IINNW 

Automate Your Wheel Strategy on NXLIW

With Tiblio's Option Bot, you can configure your own wheel strategy including NXLIW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NXLIW
  • Rev/Share 0.0098
  • Book/Share 0.1747
  • PB 6.81
  • Debt/Equity 0.0
  • CurrentRatio 4.5596
  • ROIC -3.7363

 

  • MktCap 20441736.0
  • FreeCF/Share -0.3425
  • PFCF -4.4856
  • PE -1.8512
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -2.7796

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Nexalin Technology, Inc. (NXLIW)

  • IPO Date
  • Website https://www.nexalin.com
  • Industry Medical - Devices
  • CEO Mr. Mark White
  • Employees 6

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.